Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
No Placebo
Drugs
Locations
Clinical Specialty
2001-2020 of 2,251 trials

Heart Attack Treatment: Evolocumab vs. Standard Care

We are studying whether the medication evolocumab can better prevent heart-related problems compared to standard treatments for patients who have recently had a heart attack. This trial focuses on improving cholesterol control and reducing hospitalizations.

Heart Attack>2 yearsMonitoring phase (IV)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteCardiologyInternal Medicine

Pancreatic Cancer: Napabucasin with Chemotherapy

We are studying how well Napabucasin works with chemotherapy for patients with metastatic pancreatic cancer after previous treatments have failed. The goal is to see if this combination improves survival and quality of life compared to standard care.

Metastatic Pancreatic CancerEfficacy phase (II)Confirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Hereditary Angioedema: BW-20805 Study

We are investigating the effects and safety of BW-20805 in adults with hereditary angioedema. The study aims to see if it can help reduce the number of HAE attacks.

Hereditary Angioedema1-2 yearsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesAllergologyInternal Medicine

Ketamine Therapy for Obsessive-Compulsive Disorder

We are studying whether ketamine can effectively reduce symptoms of obsessive-compulsive disorder. This trial will help us understand its impact on mental function during stressful situations.

Obsessive Compulsive Disorder (OCD)≤3 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemotePsychiatry

Growth Hormone and Liver Fat Metabolism Study

We are investigating how growth hormone influences fat processing in the liver of healthy adults. Additionally, we will explore its effects in patients with acromegaly to understand fat secretion better.

AcromegalyHealthy Participants≤3 monthsEfficacy phase (II)No PlaceboStandard MedicinesEndocrinologyHepatology

Prolonged Grief Disorder: PEX010 Treatment

We are testing a new treatment called PEX010 for people experiencing prolonged grief disorder. The study aims to see if it can significantly reduce grief symptoms and explore the effects of self-touch.

Prolonged Grief Disorder≤3 monthsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemotePsychiatry

Non-Small Cell Lung Cancer: Drug Sequencing Study

We are investigating the best order to use two medications for patients with advanced non-small cell lung cancer that has specific mutations. This study aims to see which treatment sequence may improve outcomes for these patients.

Non-small Cell Lung Cancer (NSCLC)>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Metastatic Non-Small-Cell Lung Cancer: Tedopi Combinations

We are studying the effects of Tedopi combined with either docetaxel or nivolumab in patients with advanced lung cancer who have not responded to previous treatments. This trial aims to see if these combinations can improve survival rates and overall health.

Metastatic Non-Small-Cell Lung Cancer1-2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesOncology

Dopamine Changes in Depression: Escitalopram vs. Bupropion

We are studying how rewards affect dopamine levels in the brain of people with major depressive disorder compared to healthy volunteers. This trial also looks at how two different antidepressants may influence these changes.

Major Depression>2 yearsMonitoring phase (IV)11-15 visitsNo PlaceboStandard MedicinesPsychiatry

Acute Myeloid Leukemia: NOPHO-DBH AML 2012 Study

We are researching new treatment options for children and adolescents with acute myeloid leukemia. The goal is to find more effective therapies while reducing side effects and improving overall outcomes.

Acute Myeloid Leukemia>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesOncologyPediatrics

Psychiatric Disorders: Immunotherapy Study

We are testing whether immunotherapy can help patients with psychotic symptoms and autoimmune conditions when added to their ongoing psychiatric care. This study aims to improve understanding of treatment options for these patients.

Mental Disorder1-2 yearsConfirmation phase (III)No PlaceboStandard MedicinesPsychiatry

Primary Plasma Cell Leukemia: New Treatment with Bortezomib and Daratumumab

We are studying a combination of medications for people with primary plasma cell leukemia to see if it improves treatment outcomes and safety. This trial will help us understand how well this new approach works compared to current treatments.

Plasma Cell Leukemia>2 yearsEfficacy phase (II)>20 visitsNo PlaceboStandard MedicinesHematologyOncology

Atorvastatin for Patients with Chronic Myeloproliferative Neoplasms

We are studying whether atorvastatin can improve health markers in patients with specific blood disorders. This trial looks at its effects alongside standard treatments to see how it may help manage symptoms and disease progression.

Blood Cancer3-6 monthsEfficacy phase (II)No PlaceboInvestigational MedicinesHematologyInternal Medicine

Lung Cancer: JNJ-90301900 with Chemoradiation

We are studying a new drug combined with standard treatments for patients with advanced non-small cell lung cancer. The goal is to see if this combination improves treatment response.

Locally Advanced Non-Small Cell Lung CancerEfficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteOncology

Lung Health: Avalyn Inhaled Antifibrotic Study

We are studying the long-term safety and effects of Avalyn's inhaled antifibrotic medications on lung function in patients who have previously participated in related trials.

Pulmonary FibrosisEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemotePulmonology

Cirrhosis: Carvedilol for Preventing Digestive Bleeding

We are studying whether Carvedilol can help prevent digestive bleeding in patients with cirrhosis. The trial measures its effects on liver pressure and overall tolerance over three months.

Cirrhotic Portal Hypertension3-6 monthsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesGastroenterologyInternal Medicine

Advanced GEP-NET: [177Lu]Lu-DOTA-TATE Treatment Study

We are testing a new treatment combining [177Lu]Lu-DOTA-TATE and octreotide LAR for patients with advanced Grade 1 and Grade 2 GEP-NET. The goal is to see if it can better delay disease progression and improve quality of life compared to existing therapies.

Gastroenteropancreatic Neuroendocrine Tumors1-2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesOncology

Transthyretin Amyloidosis with Cardiomyopathy: Vutrisiran Study

We are evaluating the safety and effectiveness of vutrisiran in patients with transthyretin amyloidosis and heart issues. This study includes those continuing treatment or switching from another medication.

Cardiac Amyloidosis>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementCardiologyInternal Medicine

Esophageal Cancer: Tislelizumab for Elderly Patients

We are studying Tislelizumab to see if it helps elderly patients with advanced esophageal cancer who cannot receive chemotherapy. The trial aims to assess survival rates and quality of life improvements.

Esophageal Squamous Cell Carcinoma3-6 monthsEfficacy phase (II)No PlaceboStandard MedicinesOncology

HER2-Positive Metastatic Breast Cancer: [177Lu]Lu-ABY-271 Treatment

We are studying a new treatment to see if it is safe and how it distributes in the body for patients with HER2-positive metastatic breast cancer. This trial will help us understand its effects on tumors and normal organs.

HER2-positive Metastatic Breast Cancer3-6 monthsSafety phase (I)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology